Literature DB >> 8460571

Topical effect of bromocriptine on rat-transplanted human prolactinomas.

B Açikgöz1, T Ozgen, O E Ozcan, S Ruacan, T Erbengi, M Sumnu.   

Abstract

In prolactinoma surgery, especially in macro-adenomas, it is not always possible to remove the tumour totally. Cell remnants may cause a regrowth and continue hypersecretion. In order to find out whether tumour remnants could be destroyed by local application of bromocriptine, a research model has been designed. First, prolactin secreting pituitary tumours, removed during surgery, were implanted bilaterally into the brain tissue of rats. In eight rats, the viability of tumour transplants was proven histopathologically and their prolactin secretion was shown immunocytochemically. In a second step, on eight rats, sterile bromocriptine solution was applied topically to the tumour transplants on one side. The other side served as control. Histopathological examination of these treated tissues revealed fibrosis. Immunocytochemical analysis showed no secretory activity. Ultrastructural investigations also revealed evidence of degeneration of the treated cells. The natural course of the transplanted tumour tissues of the other side, as a control group, was also observed during the same 55-day period.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8460571     DOI: 10.1007/bf02112038

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  13 in total

1.  The heterologous intracerebral transplantation of human brain tumors.

Authors:  H MIYAWAKI; S ISHII
Journal:  Arch Pathol       Date:  1960-10

2.  The inhibition of prolactin secretion in man by CB-154 (2-Br-alpha-ergocryptine).

Authors:  E Del Pozo; R B Del Re; L Varga; H Friesen
Journal:  J Clin Endocrinol Metab       Date:  1972-11       Impact factor: 5.958

3.  Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study.

Authors:  G T Tindall; K Kovacs; E Horvath; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1982-12       Impact factor: 5.958

4.  Structural changes in human pituitary tumor after bromocriptine therapy.

Authors:  S S Rengachary; T Tomita; B F Jefferies; I Watanabe
Journal:  Neurosurgery       Date:  1982-02       Impact factor: 4.654

5.  Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas.

Authors:  A M Landolt; H Minder; V Osterwalder; T A Landolt
Journal:  Experientia       Date:  1983-06-15

6.  Effects of bromocriptine on prolactin-secreting pituitary adenomas. Mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis.

Authors:  H Mori; S Mori; Y Saitoh; N Arita; T Aono; T Uozumi; H Mogami; K Matsumoto
Journal:  Cancer       Date:  1985-07-15       Impact factor: 6.860

7.  Estrone-induced, prolactin-secreting and dopamine-sensitive rat pituitary tumor.

Authors:  M Lis; M Cantin; A M Marchisio; D Eljarmak; R Collu
Journal:  Eur J Cancer Clin Oncol       Date:  1984-06

8.  Necrotic changes in prolactinomas after long term administration of bromocriptine.

Authors:  M Gen; T Uozumi; M Ohta; A Ito; H Kajiwara; S Mori
Journal:  J Clin Endocrinol Metab       Date:  1984-09       Impact factor: 5.958

9.  Inhibition of prolactin secretion and synthesis by dopamine, noradrenaline and pilocarpine in cultured rat pituitary tumour cells.

Authors:  S Bang; K M Gautvik
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1977-10

10.  Ergot-induced inhibition of pituitary tumor growth in rats.

Authors:  S K Quadri; K H Lu; J Meites
Journal:  Science       Date:  1972-04-28       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.